| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zhang,Nian-Yuan | Chairman | 0.42% | |
| Zheng,Jia-Jing | Director | 14.62% | NATIONAL DEVELOPMENT FUND MANAGEMENT COMMITTEE, EXECUTIVE YUAN |
| Lin,Shi-Jia | Director | 14.62% | NATIONAL DEVELOPMENT FUND MANAGEMENT COMMITTEE, EXECUTIVE YUAN |
| Chen,Zhi-Quan | Director | 0.24% | ZHANG CHUN INVESTMENT CO., LTD. |
| Li,Tian-Jie | Director | 6.63% | HUI HONG INVESTMENT CO., LTD. |
| Ceng,Da-Meng | Director | 1.05% | YI TAI INVESTMENT CO., LTD. |
| Qiu,Qin-Ting | Independent Director | 0.00% | |
| Lin,Guo-Feng | Independent Director | 0.00% | |
| Li,Shi-Ren | Independent Director | 0.00% |
Change Capital to 4,000,000,000
2024/07/03
Change Company Name to Taimed Biologics Inc.
2023/11/30
Change Company Name to Taimed Biologics Inc.
2023/09/01
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2023/09/01
Change Company Name to Taimed Biologics Inc.
2023/06/01
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2023/06/01
Change Company Name to Taimed Biologics Inc.
2023/03/07
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2023/03/07
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2022/12/05
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2022/09/06
Change Company Name to Taimed Biologics Inc.
2022/09/06
Change Capital to 3,000,000,000
2019/05/14
Change Person in Charge to Zhang,Nian-Yuan
2018/05/09
Change Capital to 2,600,000,000
2015/12/17
Change Person in Charge to Chen,Zhi-Quan
2013/06/21
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 176,241 | 610,162 | 491,777 |
| Operating cost | 84,972 | 398,937 | 266,544 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 91,269 | 211,225 | 225,233 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 91,269 | 211,225 | 225,233 |
| Operating expenses | 124,600 | 463,493 | 391,464 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -33,331 | -252,268 | -166,231 |
| Non-operating income and expenses | 7,529 | 50,436 | -28,579 |
| Net profit (loss) before tax | -25,802 | -201,832 | -194,810 |
| Income tax expense (benefits) | 0 | 0 | 0 |
| Net profit (loss) of ongoing business for the current period | -25,802 | -201,832 | -194,810 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -25,802 | -201,832 | -194,810 |
| Other comprehensive profit (loss), net | 2,794 | -7,763 | 183 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -23,008 | -209,595 | -194,627 |
| Net profit (loss) attributable to owners of parent company | -25,802 | -201,832 | -194,810 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -23,008 | -209,595 | -194,627 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 0 | 0 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 45,762 | -379,552 | -25,601 |
| Net cash inflows (outflows) from investing activities | 55,482 | -714,842 | -16,455 |
| Net cash inflow (outflow) from financing activities | -4,527 | 1,412,079 | 19,232 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 2,000 | 11,538 | -279 |
| Increase (decrease) in cash and cash equivalents in the current period | 98,717 | 329,223 | -23,103 |
| Beginning balance of cash and cash equivalents | 580,230 | 251,007 | 274,110 |
| Ending balance of cash and cash equivalents | 678,947 | 580,230 | 251,007 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 3,342,765 | 3,393,658 | 2,151,398 |
| Non-current asset | 1,587,667 | 1,605,589 | 1,742,524 |
| Total asset | 4,930,432 | 4,999,247 | 3,893,922 |
| Current liability | 138,615 | 134,765 | 361,172 |
| Non-current liability | 785,437 | 841,573 | 966,664 |
| Total liability | 924,052 | 976,338 | 1,327,836 |
| share capital | 2,731,192 | 2,730,815 | 2,530,097 |
| Equity - secruity token | - | - | - |
| capital reserve | 2,458,474 | 2,452,372 | 986,672 |
| retained earning | -1,162,189 | -1,136,387 | -934,555 |
| Other equity | -21,097 | -23,891 | -16,128 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 4,006,380 | 4,022,909 | 2,566,086 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 4,006,380 | 4,022,909 | 2,566,086 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 14 | 14 | 10 |
